The Ministry of Health, Labor and Welfare (MHLW) on December 10 officially revealed the overview of its distribution and storage plans in Japan for three frontrunner COVID-19 vaccines being developed by Pfizer, Moderna, and AstraZeneca, along with their characteristics known…
To read the full story
Related Article
- MHLW Says 7,500 Vaccine Freezers for Storage at Minus 20 Degrees C, Presumably for Moderna Shot
November 30, 2020
- MHLW Scrambling to Set Up Vaccination System for Ultracold-Chain Required COVID-19 Vaccine
November 26, 2020
- MHLW to Prepare 7,500 More Freezers for COVID-19 Vaccine Storage at Medical Institutions
November 25, 2020
- MHLW Expects Use of Dry Ice-Fitted Cooling Boxes to Deliver Ultracold Chain-Required COVID-19 Shots: Official
November 19, 2020
REGULATORY
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





